BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 4064050)

  • 1. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control.
    Staab HJ; Ahlemann LM; Anderer FA; Zwirner M; Schindler AE
    Cancer Detect Prev; 1985; 8(1-2):35-45. PubMed ID: 4064050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
    Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
    Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
    Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The tumor markers TPA and CEA in the after care of breast cancer].
    Beaufort F; Fueger GF; Steiner H
    Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
    Paulick R; Caffier H; Paulick M
    Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tissue polypeptide and carcinoembryonic antigens in patients with breast cancer].
    Polevaia EB; Tkacheva GA; Ivanov VM; Koposova TL
    Vopr Onkol; 1984; 30(3):9-13. PubMed ID: 6710954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
    Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
    Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA.
    Janku F; Srovnal J; Korinkova G; Novotny J; Petruzelka L; Power D; Matous B; Hajduch M
    Neoplasma; 2008; 55(4):317-22. PubMed ID: 18505343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Human breast cancer markers].
    Remennik LV
    Eksp Onkol; 1985; 7(4):3-8. PubMed ID: 2994992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of carcinoembryonic and tissue polypeptide antigen determination in the diagnosis of metastases in breast cancer.
    Kausitz J; Hupka S; Makaiová I; Michalíková B; Urbanová M; Bohunický L; Belovicová C
    Neoplasma; 1986; 33(4):471-6. PubMed ID: 3762808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
    Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
    Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
    Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients.
    Marchetti A; Buttitta F; Bertacca G; Zavaglia K; Bevilacqua G; Angelucci D; Viacava P; Naccarato A; Bonadio A; Barassi F; Felicioni L; Salvatore S; Mucilli F
    J Pathol; 2001 Sep; 195(2):186-90. PubMed ID: 11592097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.